On Monday, WPCS International Incorporated (NASDAQ:WPCS)’s shares declined -17.39% to $0.190, as WPCS International Incorporated, declared that its domestic operation was awarded $14.4 million in new contracts during the month of March 2015. Sebastian Giordano, Interim CEO of WPCS, commented, “While we continue our corporate restructuring efforts, we are extremely happy to see our core Suisun City business continue to capitalize upon its stellar reputation as a leading provider of low voltage and structured building communications cabling.
WPCS International Incorporated provides low voltage communication infrastructure services in the public services, healthcare, energy, and corporate enterprise markets worldwide.
Real Goods Solar, Inc. (NASDAQ:RGSE)’s shares dropped -4.31% to $0.220, during the last trading session on Monday, hitting its lowest level, as RGS Energy, one of the nation’s largest and most recognized rooftop installers of solar equipment, and OneRoof Energy, Inc., a leading residential solar services provider and wholly-owned partner of OneRoof Energy Group, Inc. (ON.V), have reached an contract to jointly offer comprehensive solar solutions to residential solar customers in New York, Massachusetts and California.
RGS Energy will originate residential solar power purchase contract (PPA) projects with RGS Financing, Inc., the in-house solar financing division for RGS Energy, with the OneRoof Energy partnership allowing RGS to expand its in-house financing to new states and further broaden its product offering to comprise PPAs. OneRoof Energy will provide the funding for RGS Energy’s in-house financing for PPAs, in addition to perform engineering, procurement, permitting and construction (EPC) services. The integrated solution offers solar customers an array of flexible financing options, seamless panel design, permitting, installation, project administration and lifetime monitoring.
Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction corporation in the United States. It operates in three segments: Residential, Sunetric, and Other.
At the end of Monday’s trade, Basic Energy Services, Inc (NYSE:BAS)‘s shares dipped -7.81% to $7.67, as Basic Energy Services, stated selected operating data for the month of March 2015. Basic’s well servicing rig count remained unchanged at 421. Well servicing rig hours for the month were 56,000 producing a rig utilization rate of 55%, contrast to 55% and 75% in February 2015 and March 2014, respectively.
During the month, Basic’s fluid service truck count reduced by 26 to 1,023. Fluid service truck hours for the month were 202,900 contrasts to 184,100 and 211,000 in February 2015 and March 2014, respectively.
Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. Its Completion and Remedial Services segment offers pumping services, such as cementing, acidizing, fracturing, nitrogen, and pressure testing; rental and fishing tools; coiled tubing; snubbing services; thru-tubing; cased-hole wireline services; and underbalanced drilling in low pressure and fluid sensitive reservoirs.
Cytori Therapeutics Inc (NASDAQ:CYTX), ended its Monday’s trading session with -5.65% loss, and closed at $1.17, as Cytori Therapeutics, declared preliminary 12 month follow-up data from the 12 patient investigator initiated Scleradec-I clinical trial conducted by Prof. B. Granel and Prof. G. Magalon from the Assistance Publique des Hôpitaux de Marseille.
In the formerly published six month follow-up data, Cytori’s ECCS-50 therapeutic showed:
Improvement in Cochin Hand Function Scale (CHFS) from mean of 48.5 at baseline to 21.2 at six months.
Improvement in Hand Pain (Visual Analog Scale) from mean of 59.4 at baseline to 17.8 at six months.
Improvement in Raynaud’s Condition Score (RCS) from mean of 7.2 at baseline to 2.9 at six months.
Cytori Therapeutics, Inc., a biotechnology corporation, develops cell therapeutics for specific diseases and medical conditions. The corporation primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
